STOCK TITAN
  1. Home
  2. News
  3. MYMD

MyMD Pharmaceuticals Inc - MYMD STOCK NEWS

Welcome to our dedicated news page for MyMD Pharmaceuticals (Ticker: MYMD), a resource for investors and traders seeking the latest updates and insights on MyMD Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect MyMD Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of MyMD Pharmaceuticals's position in the market.

News
MyMD Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing
Rhea-AI Summary
MyMD Pharmaceuticals, Inc.® (Nasdaq: MYMD) has regained compliance with Nasdaq's minimum bid price requirement after a 1-for-30 reverse stock split, ensuring continued listing on the Nasdaq Capital Market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.54%
Tags
none
-
News
MyMD Pharmaceuticals Announces Reverse Stock Split to Maintain Nasdaq Listing
Rhea-AI Summary
MyMD Pharmaceuticals, Inc. (MYMD) announces a reverse stock split of common stock at a ratio of 1:30, effective February 15, 2024, to be traded on a split-adjusted basis on the Nasdaq Capital Market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-14.49%
Tags
stock split
-
News
MyMD Pharmaceuticals Releases Positive Clinical Trial Results For Sarcopenia Treatment Drug
Rhea-AI Summary
Company X (XYZ) Develops Breakthrough Treatment for Sarcopenia
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.44%
Tags
clinical trial
News
MyMD Pharmaceuticals Plans FDA-Cleared Phase 2 Clinical Trial of MYMD-1 in Rheumatoid Arthritis
Rhea-AI Summary
MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) targets first quarter 2024 for trial initiation for their oral TNF-α inhibitor treatment for rheumatoid arthritis (RA). The company's IND application for a Phase 2 clinical trial of oral MYMD-1® was cleared by the FDA, demonstrating potential to disrupt the market for RA treatments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.6%
Tags
clinical trial
-
News
MyMD Announces Preclinical Study Results Showing Novel Cannabidiol Analog, Supera-CBD™, Reduced Acute Inflammatory Pain
Rhea-AI Summary
MyMD Pharmaceuticals announces positive results from preclinical study of Supera-CBD for inflammatory pain relief
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.61%
Tags
clinical trial
-
News
MyMD Pharmaceuticals to Present Updated Statistically Significant Phase 2 Data for MYMD-1, Potential TNF-α Market Disrupter, at BioFuture 2023
Rhea-AI Summary
MyMD Pharmaceuticals plans to share positive phase 2 study results for MYMD-1 in sarcopenia at BioFuture 2023 Meeting. The study showed a reduction in TNF-α levels in cohort 4 (1050mg) compared to placebo (p=0.002 to 0.008). MYMD-1 has potential as the first FDA-approved drug for sarcopenia. The FDA has accepted the IND for MYMD-1 in rheumatoid arthritis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.32%
Tags
conferences clinical trial
News
FDA Accepts MyMD Pharmaceuticals’ Investigational New Drug Application (IND) for Phase 2 Study of oral TNF-α inhibitor MYMD-1® in Rheumatoid Arthritis (RA)
Rhea-AI Summary
MyMD Pharmaceuticals, Inc. has received FDA acceptance of its Investigational New Drug Application for MYMD-1, an oral TNF-α inhibitor, to evaluate its safety and efficacy in patients with active rheumatoid arthritis (RA). MYMD-1 has the potential to transform the treatment of TNF-α based diseases due to its selectivity and ability to cross the blood-brain barrier. It can be taken orally, unlike currently available TNF-α inhibitors that require injection or infusion. MYMD-1 has shown to block both TNF-α and IL-6 activity, making it doubly effective at inhibiting inflammation. The Phase 2 study in sarcopenia showed promising biomarker data, and the company plans to initiate Phase 3 trials. If approved, MYMD-1 could be the first drug approved for sarcopenia.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.64%
Tags
clinical trial
-
News
MyMD Pharmaceuticals to Hold Conference Call Today to Discuss Phase 2 Trial Results
Rhea-AI Summary
MyMD Pharmaceuticals announces positive Phase 2 results for MYMD-1 in Sarcopenia/Age-Related Frailty
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.8%
Tags
clinical trial
-
News
MyMD Pharmaceuticals Reports Statistically Significant Positive Topline Phase 2 Results for Next Generation Oral TNF-α Inhibitor MYMD-1® in Sarcopenia/Age-Related Frailty
Rhea-AI Summary
MyMD Pharmaceuticals, Inc. (MYMD) announced positive topline results from its Phase 2 study of MYMD-1, a potential oral TNF-α inhibitor for chronic inflammation associated with sarcopenia. The study demonstrated significant reduction in inflammatory markers and met all safety and tolerability endpoints. MYMD-1 has the potential to be the first FDA-approved drug for sarcopenia, a condition linked to increased risk of hospitalization, disability, and death.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
31.82%
Tags
clinical trial
News
MyMD Pharmaceuticals® Provides Dosing Update on Phase 2 Multi-Center Clinical Trial of MYMD-1® as a Therapy for Delaying Aging and Extending Healthy Lifespan
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.54%
Tags
clinical trial
Stock MYMD logo
MyMD Pharmaceuticals Inc

Nasdaq:MYMD

MYMD Rankings

N/A Ranked by Market Cap
#5412 Ranked by Stock Gains
N/A Ranked by Dividends

MYMD Stock Data

5.18M
1.94M
1.06%
9.72%
5.22%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
West Deptford

About MYMD

mymd is a clinical stage biotech pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms. mymd-1 is a drug platform based on a clinical stage small molecule that regulates the immunometabolic system to control tumor necrosis factor alpha (tnf-α) and other pro-inflammatory cytokines. mymd-1 is being developed to treat autoimmune diseases, including those currently treated with non-selective tnf-α blocking drugs, and aging and longevity. supera-cbd is a drug platform based on a novel (patent pending) synthetic derivative of cannabidiol (cbd) that targets numerous key receptors including cb2 and opioid receptors and inhibits monoamine oxidase. supera-cbd is being developed to address the rapidly growing cbd market that includes fda approved drugs and cbd products not currently regulated as a drug.